by Clinical Neuropsychologist | Wednesday, June 26, 2024 | Dementia
Abstract INTRODUCTION Inpp5d is genetically associated with Alzheimer’s disease risk. Loss of Inpp5d alters amyloid pathology in models of amyloidosis. Inpp5d is expressed predominantly in microglia but its function in brain is poorly understood. METHODS We...
by Clinical Neuropsychologist | Wednesday, June 26, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Donna M. Wilcock, Bruce T. Lamb | June 26, 2024 Wiley:...
by Clinical Neuropsychologist | Wednesday, June 26, 2024 | Dementia
Abstract INTRODUCTION Variants of uncertain significance (VUS) surged with affordable genetic testing, posing challenges for determining pathogenicity. We examine the pathogenicity of a novel VUS P93S in Annexin A11 (ANXA11) – an amyotrophic lateral...
by Clinical Neuropsychologist | Tuesday, June 25, 2024 | Dementia
Abstract INTRODUCTION Identification of individuals with mild cognitive impairment (MCI) who are at risk of developing Alzheimer’s disease (AD) is crucial for early intervention and selection of clinical trials. METHODS We applied natural language processing...
by Clinical Neuropsychologist | Tuesday, June 25, 2024 | Dementia
Abstract INTRODUCTION The established cerebrospinal fluid (CSF) phosphorylated tau181 (p-tau181) may not reliably reflect concomitant Alzheimer’s disease (AD) and primary age-related tauopathy (PART) found in Creutzfeldt–Jakob disease (CJD) at autopsy. METHODS...